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Breast Cancer Vaccine: Are We There Yet? 
Abstract 
In lieu of an abstract, here is the article's first paragraph: 
Breast cancer is the most fatal form of cancer for female population worldwide. National Cancer Institute 
(NCI) estimates 226,870 females and 2,190 males to be diagnosed with breast cancer in the United 
States by the end of 2012. The estimated death toll for this year includes 39,510 females and 410 males, 
as reported by NCI. Statistics state that 1 in every 8 females will be diagnosed with breast cancer during 
her lifetime. These alarming numbers have provoked a large number of scientists to contribute towards 
the fight against breast cancer. Today there are various tools available for females to protect them from 
breast cancer. Mammography serves as an efficient tool in screening and catching such cases early 
enough for improved treatment, while surgery, radiotherapy and chemotherapy provide a strong line of 
treatment to breast cancer patients. Cancer patients are often subjected to a combination of such 
therapies, leading to cumulative adverse effects accompanied with the treatment. Addressing the growing 
number of breast cancer cases, the adverse effects associated with current therapies and the risk of 
having a relapse after undergoing extensive conventional therapy, researchers are now looking forward 
for a breast cancer vaccine [1-3]. 
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Breast cancer is the most fatal form of cancer for female population 
worldwide. National Cancer Institute (NCI) estimates 226,870 females 
and 2,190 males to be diagnosed with breast cancer in the United States 
by the end of 2012. The estimated death toll for this year includes 39,510 
females and 410 males, as reported by NCI. Statistics state that 1 in 
every 8 females will be diagnosed with breast cancer during her lifetime. 
These alarming numbers have provoked a large number of scientists 
to contribute towards the fight against breast cancer. Today there are 
various tools available for females to protect them from breast cancer. 
Mammography serves as an efficient tool in screening and catching such 
cases early enough for improved treatment, while surgery, radiotherapy 
and chemotherapy provide a strong line of treatment to breast cancer 
patients. Cancer patients are often subjected to a combination of such 
therapies, leading to cumulative adverse effects accompanied with the 
treatment. Addressing the growing number of breast cancer cases, the 
adverse effects associated with current therapies and the risk of having 
a relapse after undergoing extensive conventional therapy, researchers 
are now looking forward for a breast cancer vaccine [1-3]. 
So far vaccines have been very effectively employed to prevent the 
infectious diseases, but the role of vaccines against cancer still remains 
to be explored. Infectious diseases are caused by pathogens, which are 
foreign in origin and thus immunizing the body to recognize these 
non-self invaders is relatively a less daunting task. However, cancer 
originates by uncontrolled growth of own cells, thus immunizing the 
body against such self-antigens is a challenge. This strongly correlates 
with the fact that we have only one US Food and Drug Administration 
(FDA) approved cancer vaccine available to us currently. Provenge/
Sipuleucel-T (Dendreon Corporation, Washington) is the only FDA 
approved therapeutic cancer vaccine against prostate cancer. Which 
involves activation of dendritic cells in presence of a prostate cancer 
antigen along with an immunostimulant. This vaccine has shown a 
marginal increase in the life span of prostate cancer patients by on an 
average of four months at a cost of $93,000. Dendreon Corporation is 
currently evaluating this approach to develop a breast cancer vaccine, 
Neuvenge/Lapuleucel-T, which uses the Human Epidermal growth 
factor Receptor 2 (HER 2) antigen as the immunogenic component of 
the vaccine b [4]. 
The HER 2 antigen has also been explored as the source of E75 
peptide vaccine, which is currently under Phase III clinical trial. The 
E75 peptide/NeuVax™ vaccine is a promising clinical trial offering 
hope to breast and ovarian cancer patients having HER 2 positive 
tumors [5]. Even the patients, whose HER 2 antigen expression is 
low (Immunohistochemisty [IHC] score of 1+/2+) can benefit from 
this vaccine. Such patients could not benefit from the well-received 
antibody therapy of Herceptin and contributed to two-third of HER 
2+ breast cancer population. NeuVax™ aims to target breast cancer 
survivors with healthy immune system, providing ample opportunity 
to the vaccine to elicit its response [3]. 
Several other breast cancer antigens such as Mucin 1 (MUC1), 
human telomerase reverse transcriptase (hTERT), tumor protein 53 
(p53), and cancer embryonic antigen (CEA) have been identified and 
employed as vaccines as well. Thus, various researchers have explored 
different breast cancer vaccines in the quest of finding the one, which 
can benefit the breast cancer patients.
On similar lines, Chablani and D’Souza et al., proposes the 
preparation of breast cancer vaccines, formulated in a particulate 
delivery system [6]. The immune response elicited by a vaccine not 
only depends on the immunogenicity of the antigen, but also the mode 
of antigen presentation [7]. A particulate delivery system enhances the 
antigen presentation of such antigenic components, thus leading to 
an efficacious vaccine. The author has reported the use of particulate 
delivery system to prepare an oral murine breast cancer vaccine, which 
was successfully tested in a female Balb/c mice model. Oral route of 
vaccine administration appears to be lucrative not only due to ease of 
administration but also due to the availability of specialized phagocytic 
M-cells present in Peyer’s patches of small intestine. These M-cells 
specialize in sampling pathogens from gut and present them to the 
immune cells housed beneath them [8,9]. Thus having a particulate 
oral breast cancer vaccine sampled by the M-cells leads to induction 
of both cellular and humoral immunity, as shown by the author. 
This oral murine breast cancer vaccine has been successfully tested 
as a prophylactic approach and currently the group is evaluating the 
efficacy of this vaccine therapeutically. 
Another alternate route of administration, which has been explored 
for influenza vaccine, recently, is the transdermal route. The vaccine 
is administered via skin with the aid of micron-sized needles [10]. 
These microneedles, when applied on skin, painlessly create aqueous 
conduits, which can be used to deliver the vaccine into the epidermis. 
The epidermis hosts various antigen-presenting cells (Langerhans 
cells), which are capable of activating immune cells to generate 
protective immunity. Chablani and D’Souza et al. have also explored 
this route of administration for an efficacious particulate murine breast 
cancer vaccine (data not yet published). Transdermal route of breast 
cancer vaccination did result in a protective immune response against 
tumor challenge as evaluated in a prophylactic vaccine study by the 
Chablani and D’Souza et al. 
Considering the advent of nanotechnology and the advances in the 
field of immunotherapy, we hope to have an efficacious breast cancer 
vaccine soon. 
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